Remove Branding Remove Licensing Remove Medicine
article thumbnail

How to Identify Branded Drugs with a Low Likelihood of Generic Entry as Targets for In-Licensing

Drug Patent Watch

Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. In this comprehensive guide, we’ll explore the intricacies of identifying such drugs and leveraging them for successful in-licensing opportunities.

article thumbnail

EQRx builds cancer drug pipeline as plans to challenge big pharma take shape

Bio Pharma Dive

The startup, which aims to develop lower-cost alternatives to branded medicines, has licensed two drugs from CStone Pharmaceuticals in a deal that could signal a coming price war in cancer immunotherapy.

Licensing 269
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pharmanovia signs licence deal for Aeterna Zentaris’ Ghryvelin

Pharmaceutical Technology

Pharmanovia and Aeterna Zentaris have entered an exclusive licensing agreement for the latter’s medicine Ghryvelin (macimorelin). Under the deal, Pharmanovia will acquire the exclusive rights and license to commercialise Ghryvelin in the EEA and the UK from Consilient Health.

Hormones 263
article thumbnail

Takeda signs licensing agreement with HUTCHMED for fruquintinib

Pharmaceutical Technology

It was commercially launched in the country in the same year under ELUNATE brand name. We look forward to utilising our development and commercial capabilities to expand the potential of this innovative medicine to patients beyond China. “We The submission is planned to be completed in the first half of this year.

Licensing 130
article thumbnail

STAT+: Angry at Vertex pricing of cystic fibrosis drugs, families in four countries seek to override patents

STAT News

In a bid to expand access to pricey cystic fibrosis treatments, a coalition of families and activists are petitioning four governments — South Africa, India, Brazil, and Ukraine — to make it possible to obtain generic versions of a medicine sold by Vertex Pharmaceuticals. Continue to STAT+ to read the full story…

article thumbnail

Are we measuring what matters most on uptake to medicines in England?

pharmaphorum

In the second of a two-part series, Leela Barham argues that whilst international comparisons of uptake are useful, there could be more to gain from looking at more medicines and their uptake in England rather than looking at a small set of medicines and their uptake internationally. Consistently focus on innovative medicines.

article thumbnail

STAT+: Pharmalittle: Pfizer will not license generic Covid-19 pill in China; BioMarin signs outcomes-based deal in Germany for gene therapy

STAT News

… Merck plans to take legal action against several pharmaceutical companies in China after noticing that some manufacturers were supplying Covid-19 drugs to some provinces and cities saying the medicines were authorized by Merck , Reuters reports.